| Literature DB >> 32033190 |
Katerina Georgousaki1, Nikolaos Tsafantakis1, Sentiljana Gumeni2, George Lambrinidis3, Victor González-Menéndez4, Jose R Tormo4, Olga Genilloud4, Ioannis P Trougakos2, Nikolas Fokialakis1.
Abstract
Abstract: A main cellular functional module that becomes dysfunctional during aging is the proteostasis network. In the present study, we show that benzoic acid derivatives isolated from Bjerkandera adusta promote the activity of the two main protein degradation systems, namely the ubiquitin-proteasome (UPP) and especially the autophagy-lysosome pathway (ALP) in human foreskin fibroblasts. Our findings were further supported by in silico studies, where all compounds were found to be putative binders of both cathepsins B and L. Among them, compound 3 (3-chloro-4-methoxybenzoic acid) showed the most potent interaction with both enzymes, which justifies the strong activation of cathepsins B and L (467.3 ± 3.9%) on cell-based assays. Considering that the activity of both the UPP and ALP pathways decreases with aging, our results suggest that the hydroxybenzoic acid scaffold could be considered as a promising candidate for the development of novel modulators of the proteostasis network, and likely of anti-aging agents.Entities:
Keywords: Bjerkandera adusta; benzoic acid derivatives; cathepsins activity; fungi; molecular docking; proteasome activity
Mesh:
Substances:
Year: 2020 PMID: 32033190 PMCID: PMC7036779 DOI: 10.3390/molecules25030666
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Relative (%) 26S proteasome activities of CT-L (LLVY/β5) and C-L (LLE/β1) in normal replicating (young) human fibroblasts after 24 h of treatment with the EtOAc and EtOAc-LL extracts of the strain CF-092983 at concentrations of 10 μg/mL and 1 μg/mL. Bars, ± SD (n = 3). * p < 0.05. Controls (cells treated with the vehicle/DMSO) were set to 100%.
Figure 2Relative (%) cathepsins B, L activities in normal replicating (young) human fibroblasts after 24 h of treatment with the EtOAc and EtOAc-LL extracts of the strain CF-092983 at concentrations of 10 μg/mL and 1 μg/mL. Bars, ± SD (n = 3). * p < 0.05. Controls (cells treated with the vehicle/DMSO) were set to 100%.
Figure 3Chemical structures of the isolated compounds 1-4.
Quantification results of compound 1-4 in EtOAc and EtOAc-LL extracts of CF-092983.
| Compound | EtOAc LL Extract (μg mg−1) | EtOAc Extract (μg mg−1) |
|---|---|---|
|
| 17.57 ± 0.18 | 2.68 ± 0.17 |
| 2.46 ± 0.13 | 1.03 ± 0.05 | |
| 7.99 ± 0.08 | 1.39 ± 0.12 | |
| 4.43 ± 0.04 | 0.89 ± 0.03 |
* The content of compounds 2, 3 and 4 was expressed as equivalents of compound 1.
Figure 4Relative (%) 26S proteasome activities of CT-L (LLVY/ β5) and C-L (LLE/ β1) in normal replicating (young) human fibroblasts after 24h of treatment with the compounds 1, 2, 3 and 4 at a concentration of 5 μΜ. Bars, ± SD (n = 3). * p < 0.05. Controls (cells treated with the vehicle/DMSO) were set to 100%.
Figure 5Relative (%) cathepsins B and L activities in normal replicating (young) human fibroblasts after 24 h of treatment with the compounds 1, 2, 3 and 4 at a concentration of 5 μΜ. Bars, ± SD (n = 3). ** p < 0.01. Controls (cells treated with the vehicle/DMSO) were set to 100%.
Figure 6Ligand interaction diagram of global minimum structure of compound 3 in complex with procathepsin B (A). Ribbon representation of procathepsin B in complex with global minimum structure of compound 3. Prodomain is colored with blue ribbons and cathepsin is colored with red ribbons (B).